

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER

IVD 1135

U. S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/070453

INTERNATIONAL APPLICATION NO.
PCT/FR00/02482 ✓

INTERNATIONAL FILING DATE
8 September 2000 ✓

PRIORITY DATE CLAIMED
8 September 1999 ✓

TITLE OF INVENTION: **HETEROARYLOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND
PHARMACEUTICAL COMPOSITIONS COMPRISING THEM**

APPLICANT(S) FOR DO/EO/US



CECCHI, Roberto and OLIVA, Ambrogio ✓

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application.
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An executed oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
Citation of References
Information Disclosure Statement by Applicant (Form PTO-1449)

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/070453		INTERNATIONAL APPLICATION NO. PCT/FR00/02482		ATTORNEY'S DOCKET NUMBER IVD 1135	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and international Search Report not prepared by the EPO or JPO\$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ...\$740.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)\$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	25 -20 =	5	x \$18.00	\$	90.00
Independent claims	3 - 3 =	0	x \$84.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	980.00
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$	980.00
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$	
TOTAL NATIONAL FEE =				\$	980.00
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$	980.00
				Amount to be refunded:	\$
				Charged	\$980.00
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>19-0091</u> in the amount of \$980.00 to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0091</u>. A duplicate copy of this sheet is enclosed.</p>					
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>					
SEND ALL CORRESPONDENCE TO:					
Patent Department				 SIGNATURE _____ DATE <u>March 6, 2002</u>	
Sanofi-Synthelabo Inc. 9 Great Valley Parkway P.O. Box 3026 Malvern, PA 19355 Facsimile: (610) 889-8799		27546 PATENT TRADEMARK OFFICE		Michael D. Alexander NAME 36,080 REGISTRATION NUMBER (610) 889-8802 TELEPHONE NUMBER	

10070453-030600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Filing under 35 U.S.C. § 371
Corresponding to International
Application No.: PCT/FR00/02482

Applicants: CECCHI et al.

International Filing Date: September 8, 2000

For: HETEROARYLOXYPROPANOLAMINES,
PROCESS FOR THEIR PREPARATION AND
PHARMACEUTICAL COMPOSITIONS
COMPRISING THEM

Commissioner for Patents
Box PCT
Attn: EO/US
Washington, D.C. 20231

Dear Sir:


PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the Claims:

Please amend claims 1-11, cancel claim 13, and add new claims 14-26 as follows before calculating the filing fee for the above-identified application.

1. (amended) A compound of formula (I):



where

X is N or CH;

A represents a group of formula (a) or (b)

CERTIFICATE UNDER 37 C.F.R. 1.10



Express Mail Label Number: EL676470513US

Date of Deposit: March 6, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above and is addressed to: Commissioner for Patents, Box PCT, Attn: EO/US, Washington, DC 20231.

Signature: *Jan Hylinski*

10070453-030602



R_1 represents a hydrogen atom or an $-NH_2$, $-NR_3R_4$, $-NR_3CO(C_1-C_4)Alk$ or $-NR_3SO_2(C_1-C_4)Alk$ group;

R_2 represents a hydrogen or halogen atom or a $(C_1-C_4)Alk$, $(C_1-C_4)alkoxy$, $-COOH$, $-COO(C_1-C_4)Alk$, $-CN$, $-CONR_3R_4$, $-NO_2$, $-SO_2NR_3R_4$ or $-NHSO_2(C_1-C_4)Alk$ group;

m and n each represent 0, 1 or 2;

R_3 and R_4 each represent a hydrogen atom or a $(C_1-C_4)Alk$ group;

Y_1 and Y_2 each represent NH or O ;

or a salt or solvate thereof.

2. (amended) A compound as claimed in claim 1, where X represents CH .

3. (amended) A compound as claimed in claim 1, where X represents a nitrogen atom and the R_2 group is in the 5-position.

4. (amended) A compound as claimed in claim 1, where the $(C_1-C_4)Alk$ group is a methyl or ethyl group.


5. (amended) A compound as claimed in claim 1, where R_2 is chosen from $-COOH$, $-COO(C_1-C_4)Alk$, $-CN$, $-NO_2$, $-CONR_3R_4$ and $-NHSO_2-(C_1-C_4)Alk$.

6. (amended) 3-[1-(5-Ethoxycarbonylpyrid-2-yl)-4-piperidinylamino]-1-(1,2-dihydro-2-oxobenzimidazol-4-yloxy)-2-propanol or a salt or solvate thereof.


7. (amended) 3-[1-(5-Ethoxycarbonylpyrid-2-yl)-4-piperidinylamino]-1-[2-aminopyrid-5-yloxy]-2-propanol or a salt or solvate thereof.

8. (amended) A process for the preparation of the compound of claim 1 wherein an epoxide of formula (II):

20070453 030602




in which A' represents the group (a) or the group (b) in which R₁ is optionally protected, where (a), (b) and R₁ are as defined in claim 1, is reacted with an amine of formula (III)




where m, n, R₂ and X are as indicated above, the protective group optionally present is removed and, optionally, the product of formula (I) thus obtained is converted into one of its salts or solvates.

9. (amended) A process for the preparation of the compound of claim 1 where A represents a group (b) and R₁ is an NH₂ group, wherein a product of formula (II) as defined in claim 8 where A' is the group (b) and R₁ is a group of formula:




is reacted with an amine of formula III and the product of formula IV thus obtained:




is subjected to a hydrogenation reaction in order to convert the 4-nitrophenyldiazenyl group to an amino group and, optionally, the product of formula (I) thus obtained is converted into one of its salts or solvates.


10. (amended) A process for the preparation of the compound of claim 1 where A represents the group (a) and Y_1 and Y_2 represent a nitrogen atom, wherein a compound of formula (V):



is reacted with a compound of formula (III) as defined in claim 8, the nitro group of the product of formula (VI) thus obtained:



is reduced, the product of formula (VII) thus obtained:



is treated with a carbonylation agent, the product of formula (I) thus obtained is isolated and, optionally, is converted into one of its salts or solvates.

20090601 10070453 030602

11. (amended) A process as claimed in claim 10 wherein the carbonylation agent is chosen from carbonyldiimidazole and phosgene.

Please cancel claim 13.

Please add the following new claims:


14. A pharmaceutical composition comprising a compound according to claim 2.
15. A pharmaceutical composition comprising a compound according to claim 3.
16. A pharmaceutical composition comprising a compound according to claim 4.
17. A pharmaceutical composition comprising a compound according to claim 5.
18. A pharmaceutical composition comprising a compound according to claim 6.
19. A pharmaceutical composition comprising a compound according to claim 7.
20. A method for treating pathologies that are improved by β_3 agonist activity which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.
21. A method for treating pathologies that are improved by β_3 agonist activity which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.
22. A method for treating pathologies that are improved by β_3 agonist activity which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.
23. A method for treating pathologies that are improved by β_3 agonist activity which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 4.
24. A method for treating pathologies that are improved by β_3 agonist activity which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 5.
25. A method for treating pathologies that are improved by β_3 agonist activity which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 6.
26. A method for treating pathologies that are improved by β_3 agonist activity which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 7.

Claims 1-11 have been amended in order to write these claims in the appropriate U.S. claim format.

Claims 14-26 have been added by the foregoing amendments. Support for claims 15-19 occurs, for example, at page 12, lines 14-18 of the specification. Support for claims 20-26 occurs, for example, at page 14, line 26 to page 15, line 4 of the specification.

Attached hereto is a marked-up version of the changes made to the claims by the instant amendment. The marked-up version is entitled “Version With Markings To Show Changes Made”.

Date: March 6, 2002


Michael D. Alexander
Reg. No. 36,080


Address
Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Telephone No. (610) 889-8802
Facsimile: (610) 889-8799

REPORT

Version With Markings to Show Changes MadeIn the Claims:

Claims 1-11 have been amended as follows:



1. (amended) A compound of formula (I):



where

X is N or CH;

A represents a group of formula (a) or (b)



R₁ represents a hydrogen atom or an -NH₂, -NR₃R₄, -NR₃CO(C₁-C₄)Alk or -NR₃SO₂(C₁-C₄)Alk group;

R₂ represents a hydrogen or halogen atom or a (C₁-C₄)Alk, (C₁-C₄)alkoxy, -COOH, -COO(C₁-C₄)Alk, -CN, -CONR₃R₄, -NO₂, -SO₂NR₃R₄ or -NHSO₂(C₁-C₄)Alk group;

m and n each represent 0, 1 or 2;

R₃ and R₄ each represent a hydrogen atom or a (C₁-C₄)Alk group;

Y₁ and Y₂ each represent NH or O;

and their salts or solvates or a salt or solvate thereof.

2. (amended) The A compound as claimed in claim 1, where X represents CH.

3. (amended) The A compound as claimed in claim 1, where X represents a nitrogen atom and the R₂ group is in the 5-position.


4. (amended) The A compound as claimed in claim 1, where the (C₁-C₄)Alk group is a methyl or ethyl group.

5. (amended) The A compound as claimed in claim 1, where R₂ is chosen from -COOH, -COO(C₁-C₄)Alk, -CN, -NO₂, -CONR₃R₄ and -NHSO₂-(C₁-C₄)Alk.


6. (amended) 3-[1-(5-Ethoxycarbonylpyrid-2-yl)-4-piperidinylamino]-1-(1,2-dihydro-2-oxobenzimidazol-4-yloxy)-2-propanol ~~and its salts or solvates~~ or a salt or solvate thereof.

7. (amended) 3-[1-(5-Ethoxycarbonylpyrid-2-yl)-4-piperidinylamino]-1-[2-aminopyrid-5-yloxy]-2-propanol ~~and its salts or solvates~~ or a salt or solvate thereof.

8. (amended) A process for the preparation of the compound of claim 1, ~~characterized in that~~ wherein an epoxide of formula (II):




in which A' represents the group (a) or the group (b) in which R₁ is optionally protected, where (a), (b) and R₁ are as defined in claim 1, is reacted with an amine of formula (III)




where m, n, R₂ and X are as indicated above, the protective group optionally present is removed and, optionally, the product of formula (I) thus obtained is converted into one of its salts or solvates.

20070453-030602

9. (amended) A process for the preparation of the compound of claim 1 where A represents a group (b) and R₁ is an NH₂ group, ~~characterized in that~~ wherein a product of formula (II) as defined in claim 8 where A' is the group (b) and R₁ is a group of formula:




is reacted with an amine of formula III and the product of formula IV thus obtained:




is subjected to a hydrogenation reaction in order to convert the 4-nitrophenyldiazenyl group to an amino group and, optionally, the product of formula (I) thus obtained is converted into one of its salts or solvates.


10. (amended) A process for the preparation of the compound of claim 1 where A represents the group (a) and Y₁ and Y₂ represent a nitrogen atom, ~~characterized in that~~ wherein a compound of formula (V):



is reacted with a compound of formula (III) as defined in claim 8, the nitro group of the product of formula (VI) thus obtained:



is reduced, the product of formula (VII) thus obtained:



is treated with a carbonylation agent, the product of formula (I) thus obtained is isolated and, optionally, is converted into one of its salts or solvates.

11. (amended) ~~The A~~ process as claimed in claim 10, ~~characterized in that~~ wherein the carbonylation agent is chosen from carbonyldiimidazole and phosgene.

Claim 13 has been canceled.

Claims 14-26 have been added.

10070453.030602

Heteroaryloxypropanolamines, process for their
preparation and pharmaceutical compositions comprising
them

The present invention relates to novel
5 propanolamines, to the pharmaceutical compositions
comprising them, to a process for their preparation and
to intermediates in this process.

These novel compounds have shown an agonist
activity with respect to the β_3 receptor and thus can be
10 used in the treatment of pathologies which benefit from
the activation of this receptor.


BE 902897 discloses aryloxypropanolamines
carrying a 1-substituted-4-piperidinyl group on the
amine, these compounds having a β_1 -blocking and
15 α -blocking activity.

J. Org. Chem., 1988, 63, 889-894, describes
other aryloxypropanolamines carrying a 1-substituted-
4-piperidinyl group on the amine.

It has now been found that heteroaryloxy-
20 propanolamines carrying a piperidin-4-yl or
piperidin-4-ylalkylene radical on the amine have an
agonist activity with respect to β_3 -adrenergic
receptors.


Thus, the present invention relates,
25 according to one of its aspects, to propanolamines of
formula (I)

10070453 030602




where X is N or CH;

A represents a group of formula (a) or (b)



(a)



(b)

R_1 represents a hydrogen atom or an $-NH_2$, $-NR_3R_4$, $-NR_3CO(C_1-C_4)Alk$ or $-NR_3SO_2(C_1-C_4)Alk$ group;

R_2 represents a hydrogen or halogen atom or a $(C_1-C_4)Alk$, $(C_1-C_4)alkoxy$, $-COOH$, $-COO(C_1-C_4)Alk$, $-CN$, $-CONR_3R_4$, $-NO_2$, $-SO_2NR_3R_4$ or $-NHSO_2(C_1-C_4)Alk$ group;

m and n each represent 0, 1 or 2;

R_3 and R_4 each represent a hydrogen atom or a $(C_1-C_4)Alk$ group;

Y_1 and Y_2 each represent NH or O;

and their salts or solvates.

In the present description, the term

" $(C_1-C_4)Alk$ " denotes a monovalent radical of a saturated straight- or branched-chain C_1-C_4 hydrocarbon.

The salts of the compounds of formula (I)

according to the present invention comprise both addition salts with pharmaceutically acceptable inorganic or organic acids, such as the hydrochloride,

hydrobromide, sulfate, hydrogensulfate, dihydrogen-phosphate, citrate, maleate, tartrate, fumarate, gluconate, methanesulfonate, 2-naphthalenesulfonate, and the like, and addition salts which make possible

5 suitable separation or crystallization of the compounds of formula (I), such as the picrate or oxalate, or addition salts with optically active acids, for example camphorsulfonic acids and mandelic or substituted mandelic acids.

10 Furthermore, when the compounds of formula (I) have a free carboxyl group, the salts also comprise the salts with inorganic bases, preferably the salts obtained with bases derived from alkali metals, such as sodium or potassium, or with organic bases.

15 The optically pure stereoisomers and the mixtures of isomers of the compounds of formula (I) form part of the present invention.

Preferred compounds of the present invention comprise the compounds of formula (I) where X
20 represents CH.

Other preferred compounds of the present invention are those where X represents nitrogen and the R₂ group is in the 5-position.

Other preferred compounds are those where the
25 (C₁-C₄)Alk group is a methyl or ethyl group.

Other preferred compounds are those where R₂ is chosen from -COOH, -COO(C₁-C₄)Alk, -CN, -NO₂,

40070453.030602

-CONR₃R₄, -NHSO₂-(C₁-C₄)Alk and Cl.


Other compounds preferred still are those where n and m are each zero.

The optionally salified compound


5 3-[1-(5-ethoxycarbonylpyrid-2-yl)-4-piperidinylamino]-1-[1,2-dihydro-2-oxobenzimidazol-4-yloxy]-2-propanol is particularly advantageous.

Another particularly advantageous compound is optionally salified 3-[1-(5-ethoxycarbonylpyrid-2-yl)-4-piperidinylamino]-1-[2-aminopyrid-5-yloxy]-2-propanol.

The compounds of formula (I) are prepared by treating an epoxide of formula (II):




where A' represents the group (a) or the group (b) in which R₁ is optionally protected by a protective group, with an amine of formula (III):




where m, n, R₂ and X are as indicated above, the protective group optionally present being removed and the product of formula (I) thus obtained being converted into one of its salts or solvates.

Alternatively, when A represents a group (b) and R_1 is an NH_2 group, the compounds of formula (I) are preferably prepared by condensation of an amine of formula (III) with a product of formula (II) where A' is the group (b) and R_1 is a group of formula:




and by subjecting the product of formula (IV) thus obtained:




(IV)

to a hydrogenation reaction in order to convert the 4-nitrophenyldiazenyl group to an amino group, and optionally the product of formula (I) thus obtained is converted into one of its salts or solvates.


When A is a group of formula (a) and Y_1 and Y_2 represent a nitrogen atom, it is also possible to prepare the compounds of formula (I) by treating a compound of formula (V):



with an amine of formula (III), by reducing the nitro group of the product of formula (VI) thus obtained:



and by treating the product of formula (VII) thus obtained:



with a carbonylation agent, namely an agent capable of inserting a carbonyl group into the molecule, such as, for example, carbonyldiimidazole or phosgene, to produce the final product, which can optionally be converted into one of its salts or solvates.

The reaction for the reduction of the nitro group to an amino group can be carried out, for example, by catalytic hydrogenation. Use may be made,

as reaction solvent, of, for example, a polar protic solvent, such as water, acetic acid or an alcohol, for example ethanol, methanol or isopropanol, an ester, for example ethyl acetate, a linear or cyclic ether, for example tetrahydrofuran or dioxane, or an aromatic solvent, for example benzene or toluene.

The cyclization reaction is preferably carried out using carbonyldiimidazole in an inert solvent, such as tetrahydrofuran or a linear ether, at a temperature of between ambient temperature and the reflux temperature of the solvent chosen.

The reaction between the epoxides and the amine (III) is carried out in an organic solvent, such as a lower alcohol, for example methanol, ethanol or isopropanol; dimethyl sulfoxide; a linear or cyclic ether; or an amide, for example dimethylformamide or dimethylacetamide, and by using at least equimolecular amounts of the reactants, optionally a slight excess of amine.

The reaction temperature is between ambient temperature and the reflux temperature of the solvent chosen.


The compounds of formula (II) in which A' is a group (a) can be prepared according to the general process disclosed in scheme III of WO97/10825 or according to Patent DE 2700193.

The compounds of formula (II) where A' is a

group (b) can be prepared according to the general process disclosed in EP 0 611 003.


The amines of formula (III) can be prepared by reaction of the appropriate synthons of formula

5 (VIII):




where Hal represents a halogen and R_2 , m and X are as defined above, with a piperidine of formula (IX):

10



where n is as defined above and P' represents a protective group, in an organic solvent, in the presence of a base, followed by the removal of the P'

15 group from the compounds of formula (X) thus obtained:



Use may be made, as reaction solvent, of, for example, dimethylformamide, pyridine, dimethyl sulfoxide, a linear or cyclic ether or a chlorinated solvent, such as dichloromethane.

Use may be made, as base, of, for example, an alkaline hydroxide, an alkaline carbonate, such as potassium carbonate, or a tertiary amine, such as triethylamine.

5 The above condensation reaction is complete in a few hours, normally in 2 to 12 hours.

The reaction temperature is between ambient temperature and the reflux temperature of the solvent chosen.

10 Use may be made, as protective groups P', of acyl groups, such as formyl, acetyl, propionyl, phenylacetyl, phenoxyacetyl and the like; an alkoxy-carbonyl group, such as tert-butoxycarbonyl and the like; an alkoxy carbonyl group, such as methoxypropionyl
15 and the like; a substituted alkoxy carbonyl group, such as monochloromethylcarbonyl, dichloromethylcarbonyl, trichloromethylcarbonyl, trichloroethylcarbonyl, trichloropropylcarbonyl, trifluoromethylcarbonyl and the like; a substituted arylalkoxycarbonyl group, such
20 as 4-nitrobenzyloxycarbonyl and the like; a benzyl group; a substituted benzyl group; an optionally substituted diphenylmethyl group; an optionally substituted trityl group, such as 4-methoxyphenyldi-phenylmethyl or di(4-methoxyphenyl)phenylmethyl; or a
25 silylating group, such as trimethylsilyl or ethyldimethylsilyl or tert-butyldimethylsilyl and the like.

The said protective groups can be removed

according to conventional methods, for example by reduction or hydrolysis. A more detailed description of these amino-protective groups and the methods for their preparation and their removal are given, for example,

5 by T. W. Greene, "Protective Groups in Organic Synthesis", John Wiley & Sons, 1981 and by J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, 1973.

10 These protective groups are removed according to the standard methods described for the protective group chosen; in the case of *tert*-butoxycarbonyl, by the removal, the cleavage is normally carried out by acid hydrolysis.

15 The compounds of formula (I) have shown a powerful activity with respect to β_3 -adrenergic receptors. In addition, these compounds have very little toxicity; in particular, their acute toxicity is compatible with their use as medicaments for the treatment of diseases in which use is made of compounds
20 having affinity for the β_3 receptor.

The activity of the compounds of the present invention with respect to the β_3 activity was demonstrated using in vitro tests on the human colon according to the method described in EP-B-436 435 and
25 in T. Croci et al., Br. J. Pharmacol., 1997, 122, 139P.

More particularly, it has been found that the compounds of formula (I) are much more active on the

isolated colon than on the atrium and on the trachea.

These surprising properties of the compounds of formula (I) make it possible to envisage their use as medicaments with a β_3 action.

5 The compounds of formula (I) and their pharmaceutically acceptable salts may therefore be indicated, for example, in the treatment of gastro-intestinal diseases, such as irritable bowel syndrome, as modulators of intestinal motricity, as lipolytic
10 agents, antiobesity agents, antidiabetics, psychotropics, antiglaucoma agents, cicatrizants or antidepressants, or as tocolytics for preventing or delaying premature labor or for the treatment and/or prophylaxis of dysmenorrhea.

15 The use of the compounds of formula (I) above, and that of their pharmaceutically acceptable salts and solvates, for the preparation of above medicaments constitutes a subsequent aspect of the present invention.

20 For such a use, an effective amount of a compound of formula (I) or of one of its pharmaceutically acceptable salts and solvates is administered to the mammals who require such a treatment.

25 The compounds of formula (I) above and their pharmaceutically acceptable salts and solvates can be used at daily doses of 0.01 to 20 mg per kilo of body

weight of the mammal to be treated, preferably at daily doses of 0.1 to 10 mg/kg. In man, the dose can preferably vary from 0.5 mg to 1 500 mg per day, in particular from 2.5 to 500 mg, according to the age of
5 the subject to be treated, the type of treatment, prophylactic or curative, and the seriousness of the condition. The compounds of formula (I) are generally administered as a dosage unit of 0.1 to 500 mg, preferably of 0.5 to 100 mg, of active principle, one
10 to five times daily.

Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient.

Thus, according to another of its aspects,
15 the present invention relates to pharmaceutical compositions including, as active principle, a compound of formula (I) above or one of its pharmaceutically acceptable salts and solvates.

In the pharmaceutical compositions of the
20 present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, transdermal or rectal administration, the active principles of formula (I) above and their pharmaceutically acceptable salts and solvates can be administered in unit administration
25 forms, as a mixture with conventional pharmaceutical vehicles, to animals and human beings for the treatment of the above said conditions. The appropriate unit

10070453-030600

administration forms comprise oral forms, such as tablets, gelatin capsules, powders, granules and solutions or suspensions to be taken orally, sublingual and buccal administration forms, subcutaneous, intramuscular or intravenous administration forms, local administration forms and rectal administration forms.

When a solid composition is prepared in the form of tablets, the main active ingredient is mixed with a pharmaceutical vehicle, such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like. The tablets can be coated with sucrose or other appropriate materials or can be treated so that they have a prolonged or delayed activity and so that they continuously release a predetermined amount of active principle.

A preparation in the form of gelatin capsules is obtained by mixing the active ingredient with a diluent and by pouring the mixture obtained into soft or hard gelatin capsules.

A preparation in the syrup or elixir form can comprise the active ingredient in conjunction with a sweetener, preferably a calorie-free sweetener, methylparaben and propylparaben as antiseptics, and an appropriate colorant and flavoring.

The water-dispersible powders or granules can comprise the active ingredient as a mixture with

dispersing agents, wetting agents or suspending agents, such as polyvinylpyrrolidone, and with sweeteners or flavor enhancers.

The water-dispersible powders or granules can
5 comprise the active ingredient as a mixture with dispersing agents, wetting agents or suspending agents, such as polyvinylpyrrolidone, and with sweeteners or flavor enhancers.

For local administration, the active
10 principle is mixed in an excipient for the preparation of creams or ointments or is dissolved in a vehicle for intraocular administration, for example in the form of an eyewash.

For rectal administration, recourse is had to
15 suppositories which are prepared with binders which melt at the rectal temperature, for example cocoa butter or polyethylene glycols.

For parenteral administration, use is made of aqueous suspensions, saline solutions or sterile
20 injectable solutions which comprise pharmacologically compatible dispersing and/or wetting agents, for example propylene glycol or butylene glycol.

The active principle can also be formulated in the form of microcapsules, optionally with one or
25 more vehicles or additives.

According to another of its aspects, the present invention relates to a method for the treatment

of the pathologies which are improved by a β_3 -agonist action which consists in administering a compound of formula (I) or one of its pharmaceutically acceptable salts or solvates. The compounds of formula (I), in particular the compounds (I) labeled with an isotope, can also be used as laboratory tools in biochemical assays.

The compounds of formula (I) bind to the β_3 -adrenergic receptor. These compounds can therefore be used in a standard binding assay, in which use is made of an organic tissue in which this receptor is particularly abundant, and the amount of compound (I) displaced by a test compound is measured, in order to evaluate the affinity of said compound with respect to binding sites of this specific receptor.

Another specific subject matter of the present invention is thus a reagent which can be used in biochemical assays, which comprises at least one suitably labeled compound of formula (I).

The examples which follow illustrate the invention.

EXAMPLE 1

3-[1-(5-Ethoxycarbonylpyrid-2-yl)-4-piperidinylamino]-[1,2-dihydro-2-oxobenzimidazol-4-yloxy]-2-propanol.

a) 4-(tert-butoxycarbonylamino)piperidine.

25 g (0.13 mol) of 4-amino-1-benzyl-piperidine, 36.2 ml (0.26 mol) of triethylamine and

31.2 g (0.143 mol) of di-*tert*-butyl dicarbonate in 200 ml of dimethylformamide are mixed at ambient temperature for 2 hours. The mixture is poured into water, extraction is carried out with ethyl acetate, the extract is washed with water and the product thus obtained is crystallized from 200 ml of isopropyl ether. 33 g of 1-benzyl-4-(*tert*-butoxycarbonylamino)-piperidine are obtained, which product is hydrogenated in a mixture of 200 ml of ethanol and 100 ml of tetrahydrofuran in the presence of 3 g of 10% Pd/C. After filtering off the catalyst, the title compound is isolated. M.p.: 157-160°C.

b) 4-*tert*-butoxycarbonylamino-1-(5-ethoxycarbonylpyrid-2-yl)piperidine

A mixture of the product prepared above, of triethylamine and of the ethyl ester of 6-chloro-nicotinic acid is heated at 80°C for 18 hours. After cooling, water is added, extraction is carried out with ethyl acetate, the organic phase is dried over sodium sulfate and the solvent is evaporated under reduced pressure. The title compound is obtained.

M.p. 140-142°C.

c) 4-amino-1-(5-ethoxycarbonylpyrid-2-yl)piperidine (dihydrochloride hydrate)

The product of stage b) is dissolved in ethyl acetate, a 3N solution of hydrochloric acid in ethyl acetate is added and the mixture is left stirring at

ambient temperature for 10 hours. The product is filtered off and washed with acetone. The title product is obtained. M.p.: 148-150°C.

5 **d) 2-amino-3-nitro-1-(2,3-epoxypropoxy)benzene**

21.7 g (0.095 mol) of glycidyl tosylate, 10 g (0.0475 mol) of 2-amino-3-nitrophenol and 6.5 g of crushed K_2CO_3 are mixed in acetone and the mixture is heated at reflux for 18 hours. The mixture is filtered and the solvent is evaporated under reduced pressure. The crude reaction product is purified by flash chromatography, elution being carried out with a 9/1 hexane/ethyl acetate mixture. The title compound is obtained. M.p.: 76°-78°C.

15 **e) 3-[1-(5-ethoxycarbonylpyrid-2-yl)-4-piperidinyl-amino]-1-(2-amino-3-nitrophenoxy)-2-propanol**

1 g (0.00475 mol) of the compound obtained in the preceding stage is mixed with 1.53 g (0.00475 mol) of 4-amino-1-(5-ethoxycarbonylpyrid-2-yl)piperidine (stage c, base) in 50 ml of ethanol. The mixture is refluxed overnight and is evaporated under reduced pressure. The crude reaction product is purified by flash chromatography, elution being carried out with a 9/1 ethyl acetate/ethanol mixture. The title compound is obtained.

M.p.: 140-142°C.

f) 3-[1-(5-ethoxycarbonylpyrid-2-yl)-4-piperidinyl-

amino]-1-(2,3-diaminophenoxy)-2-propanol

1.71 g (0.0037 mol) of the compound of the preceding stage are hydrogenated at ambient temperature in 120 ml of ethanol in the presence of 0.8 g of 5%

5 Pd/C. After having filtered and evaporated the solvent, the crude reaction product is purified by flash chromatography, elution being carried out with a 7/3 ethyl acetate/ethanol mixture. The title compound is obtained.

10 **g) 3-[1-(5-ethoxycarbonylpyrid-2-yl)-4-piperidinyl-amino]-1-[1,2-dihydro-2-oxobenzimidazol-4-yloxy]-2-propanol**

The product obtained in the preceding stage is placed with 0.44 g of N,N-carbonyldiimidazole

15 (0.027 mol) in 50 ml of THF with stirring at ambient temperature overnight. The solvent is evaporated under reduced pressure, ethyl acetate is added and washing is carried out with water. After drying and evaporating the solvent, a first purification by chromatography is
20 carried out, elution being carried out with an 8/2 methylene chloride/methanol mixture, and a second purification by chromatography is carried out, elution being carried out with an 8/2 methanol/ethyl acetate mixture. The title product is obtained.

25 M.p.: 191°-193°C.

EXAMPLE 2

3-[1-(5-Ethoxycarbonylpyrid-2-yl)-4-piperidinylamino]-

10070453.030602

1-[2-aminopyrid-5-yloxy]-2-propanol**a) 2-[2-(4-nitrophenyl)diazenyl]-5-(2,3-epoxy-propoxy)pyridine**

1.64 ml of diethyl azodicarboxylate

5 (0.01043 mol) are added at 0°C, under a nitrogen atmosphere, to a solution containing 1.82 g of 5-hydroxy-2-(2-(4-nitrophenyl)diazenyl)pyridine (0.01043 mol), prepared according to the method described in J. Am. Chem. Soc., 1959, 81, 6049,

10 0.692 ml of 2,3-epoxypropanol (0.01043 mol) and 2.74 g of Ph₃P (0.01043 mol) in 18 ml of DMF. The mixture is allowed to react for one hour at 0°C and then for 40 hours at ambient temperature with stirring. Water is added, extraction is carried out with ethyl acetate,

15 the extract is washed and the solvent is evaporated. The crude reaction product is purified by chromatography, elution being carried out with a 100/2 CH₂Cl₂/CH₃OH mixture. The title product is obtained. M.p.: 150-152°C (dec.).

20 **b) 3-[1-(5-ethoxycarbonylpyrid-2-yl)-4-piperidinyl-amino]-1-[2-(2-(4-nitrophenyl)diazenyl)pyrid-5-yloxy]-2-propanol**

A solution of 1.15 g (0.00383 mol) of the product obtained in stage a) and 1.05 g (0.00421 mol)

25 of 1-(5-ethoxycarbonylpyrid-2-yl)-4-piperidylamine in 20 ml of ethanol is heated at reflux for 7 hours. Filtration is carried out, drying is carried out and

M.p.: 172°C.

5 amino]-1-[2-aminopyrid-5-yloxy]-2-propanol

10 temperature of between 15 and 20°C. The crude reaction product is filtered through celite and washed with ethanol. The solvent is evaporated, 30 ml of a saturated NaHCO₃ solution and 5 ml of 1N NaOH are added, and extraction is carried out with ethyl acetate. The
15 solvent is evaporated and the crude reaction product is purified by chromatography, elution being carried out with a 95/5/0.5 and subsequently 90/10/1 CH₂Cl₂/CH₃OH/NH₄OH mixture.

The title product is obtained. M.p.: 120-122°C.

20 **EXAMPLE 3**

3-[1-(5-Ethoxycarbonylpyrid-2-yl)-4-piperidinylamino]-
1-(1,2-dihydro-2-oxobenzimidazol-4-yloxy)-(2S)-
2-propanol

a) 2-Amino-3-nitro-1-((2S)-2,3-epoxypropoxy)benzene

25 5 g (0.032 mol) of 2-amino-3-nitrophenol, 8 g
 (0.032 mol) of (S)-(+)-glycidyl 3-nitrobenzenesulfonate
 and 8.9 g of K_2CO_3 are mixed in 80 ml of acetone and the

mixture is refluxed for 18 hours. Filtration is carried out, the solvent is evaporated under reduced pressure and the crude product is purified by flash chromatography, elution being carried out with a 7/3 cyclohexane/ethyl acetate mixture. The solid product obtained is triturated in ethyl ether and 5.67 g of the title product are obtained. M.p.: 107-109°. $\alpha_D = +28.1$ (c = 0.5%, MeOH).

b) 3-[1-(5-ethoxycarbonylpyrid-2-yl)-4-piperidinidyl-amino]-1-(2-amino-3-nitrophenoxy)-(2S)-2-propanol

By following the method of example 1 e) but starting from the compound prepared above, the title product is obtained. $\alpha_D = +18.3$ (c = 1% MeOH)

c) 3-[1-(5-ethoxycarbonylpyrid-2-yl)-4-piperidinidyl-amino]-1-(2,3-diaminophenoxy)-(2S)-2-propanol

By following the method of example 1 f) but starting from the compound prepared above, the title product is obtained.

d) 3-[1-(5-ethoxycarbonylpyrid-2-yl)-4-piperidinyl-amino]-1-(1,2-dihydro-2-oxobenzimidazol-4-yloxy)-(2S)-2-propanol

0.3 g (0.061 mol) of the product obtained in stage c) is placed in 4 ml of toluene and 4 ml of water with 0.059 (0.488 mol) of trichloromethyl chloroformate with stirring at ambient temperature for 4 hours.

Filtration is carried out, the product is dissolved in ethanol and aqueous ammonia, the solvent is evaporated,

purification is carried out by flash chromatography, elution being carried out with a 90/10/1 methylene chloride/methanol/aqueous ammonia mixture, and the title product is obtained. Amorphous solid.

5 **200 MHz (^1H) and 50 MHz (^{13}C) NMR spectrum:**

^1H NMR (aromatics) - ν_{TMS} (CDCl_3 , ppm): 6.3-6.6 (3H, m), 6.6-6.9 (1H, m), 7.91 (1H, dd, J_1 9 Hz, J_2 2 Hz), 8.72 (1H, d, J 2 Hz).

^{13}C NMR - ν_{TMS} (CDCl_3 , ppm): 14.3, 31.6, 31.7, 43.5, 10 48.6, 55.1, 60.3, 69.0, 71.3, 103.2, 105.0, 114.3, 118.9, 121.7, 129.9, 138.3, 143.2, 150.9, 156.7, 160.2, 165.9.

EXAMPLE 4

3-[1-(4-Ethoxycarbonylphenyl)-4-piperidinylamino]-1-
15 (1,2-dihydro-2-oxobenzimidazol-4-yloxy)-(2S)-2-propanol

a) **4-(tert-butoxycarbonylamino)piperidine**

25 g (0.13 mol) of 4-amino-1-benzyl-piperidine, 36.2 ml (0.26 mol) of triethylamine and 31.2 g (0.143 mol) of di-tert-butyl dicarbonate are
20 mixed in 200 ml of dimethylformamide at ambient temperature for 2 hours. The mixture is poured into water, extraction is carried out with ethyl acetate, the extract is washed with water and the product thus obtained is crystallized from 200 ml of isopropyl
25 ether. 33 g of 1-benzyl-4-(tert-butoxycarbonylamino)-piperidine are obtained, which product is hydrogenated in a mixture of 200 ml of ethanol and 100 ml of tetra-

hydrofuran in the presence of 3 g of 10% Pd/C. After filtering off the catalyst, the title compound is isolated.

M.p.: 157-160°C.

5 **b) 4-tert-butoxycarbonylamino-1-(4-ethoxycarbonyl-phenyl)piperidine**

21.6 g (0.10 mol) of the product obtained above are heated at 80°C for 55 hours with 9.06 g (0.01 mol) of 4-ethoxycarbonyl-1-fluorobenzene and
10 14.9 g of K₂CO₃ in 200 ml of dimethylformamide. The K₂CO₃ is filtered off, the solution is poured into water, extraction is carried out with ethyl acetate and the solvent is evaporated. The crude reaction product is
15 purified by flash chromatography, elution being carried out with an 8/2 cyclohexane/ethyl acetate mixture. The title product is obtained and is crystallized from ethyl acetate. M.p. = 138°-140°

c) 4-amino-1-(4-ethoxycarbonylphenyl)piperidine (hydrochloride)

20 9.74 g (0.023 mol) of the product obtained in c) are dissolved in 60 ml of ethyl acetate, and 80 ml of a 3N solution of HCl in ethyl acetate are added. Heating at reflux is carried out for 5 hours, the solvent is evaporated, acetone is added and the product
25 is filtered off. The title product is obtained and is crystallized with ethanol. M.p.: 240-242°.

d) 3-[1-(4-ethoxycarbonylphenyl)-4-piperidinyl]-

amino]-1-(2-amino-3-nitrophenoxy)-(2S)-propanol

By following the method of example 1 e) but using 1 g (0.0040 mol) of the compound obtained above (base) and 0.85 g (0.0040 mol) of the epoxide of

5 example 3 a), 1.24 g of the title product are obtained, after purification by flash chromatography with a 95/5 methylene chloride/methanol mixture.

M.p.: 112-114°.

e) 3-[1-(4-ethoxycarbonylphenyl)-4-piperidinylamino]-

10 **1-(2,3-diaminophenoxy)-(2S)-propanol**

By following the method of Example 1 f) but starting from 1.2 g (0.0026 mol) of the compound obtained above, 1.2 g of the title product are obtained.

15 **f) 3-[1-(4-ethoxycarbonylphenyl)-4-piperidinylamino]-
1-(1,2-dihydro-2-oxobenzimidazol-4-oxo)-(2S)-propanol**

The product obtained in the preceding stage is placed with 0.57 g (0.0029 mol) of trichloromethyl chloroformate in 20 ml of toluene and 20 ml of tetra-
20 hydrofuran (THF) with stirring at ambient temperature for 4 hours. The solvent is evaporated under reduced pressure, ethyl acetate and aqueous ammonia are added, and washing is carried out with water. The organic phase is dried over sodium sulfate, the solvent is
25 evaporated and the residue is purified by flash chromatography, elution being carried out with an 8/2 methanol/ethyl acetate mixture. 0.72 g of the title

product is obtained.

M.p.: 188-190°. $\alpha_{365} = +41.5$ ($c = 1\%$, MeOH).

EXAMPLE 5

5 3-[1-(4-*n*-Butylaminocarbonylphenyl)-4-piperidinyl-
amino]-1-(1,2-dihydro-2-oxobenzimidazol-4-oxy)-(2*S*)-
propanol

a) 4-*tert*-butoxycarbonylamino-1-(4-hydroxycarbonyl-
phenyl)piperidine

10 2.19 g (0.0063 mol) of the product of
example 4 b) are dissolved in 30 ml of THF and 20 ml of
water, and 12.6 ml (0.0126 mol) of 1N NaOH are added.
After 24 hours at ambient temperature, acetic acid is
added until a pH of 7 is achieved, the solvent is
15 evaporated, and the solid thus obtained is triturated
in water, filtered off and crystallized from ethanol.
1.32 g of the title compound are obtained. M.p. >300°.

b) 4-*tert*-butoxycarbonylamino-1-(4-*n*-butylamino-
carbonylphenyl)piperidine

20 2.5 g (0.0078 mol) of the product from the
preceding stage, 3.45 g (0.0078 mol) of (benzotriazol-
1-yloxy)tris(dimethylamino)phosphonium hexafluoro-
phosphate, 0.57 g (0.0078 mol) of *n*-butylamine and
1.7 ml (0.012 mol) of triethylamine are mixed in 80 ml
25 of methylene chloride and the mixture is heated at 40°
for 8 hours. The solvent is evaporated and ethyl
acetate and a saturated NaHCO₃ solution are added. A

10070453 030502

solid in suspension is obtained, which solid is filtered off and washed with water and then with ethyl acetate. The product is crystallized from 50 ml of isopropanol and 2.14 g of the title product are

5 obtained. M.p.: 208-210°.

c) 4-amino-1-(4-n-butylaminocarbonylphenyl)piperidine (hydrochloride dihydrate)

By following the method of example 4 c) but using the compound from the preceding stage as starting
10 material, 1.66 g of the title product are obtained, after crystallization from ethanol. M.p.: 231-235°.

d) 3-[1-(4-n-butylaminocarbonylphenyl)-4-piperidinyl-amino]-1-(2-amino-3-nitrophenoxy)-(2S)-propanol

By using 0.49 g (0.0018 mol) of the product
15 from the preceding example (base) and 0.4 g (0.0019 mol) of the epoxide of example 3a) in 20 ml of ethanol and by following the method of example 1e), 0.57 g of the title compound is obtained, after purification by flash chromatography with a 100/1
20 methanol/aqueous ammonia mixture. M.p. = 68-70°.

e) 3-[1-(4-n-butylaminocarbonylphenyl)-4-piperidinyl-amino]-1-(2,3-diaminophenoxy)-(2S)-propanol

By carrying out the preparation as in example 1 f) but using the compound obtained above as starting
25 material, 0.52 g of the title product is obtained.

f) 3-[1-(4-n-butylaminocarbonylphenyl)-4-piperidinyl-amino]-1-(1,2-dihydro-2-oxobenzimidazol-4-oxy)-(2S)-


propanol

The product obtained in the preceding stage is placed with 0.23 g (0.0012 mol) of trichloromethyl chloroformate in 20 ml of THF and 4 ml of methylene chloride with stirring at ambient temperature for 4 hours. The solvent is evaporated under reduced pressure, ethyl acetate and aqueous ammonia are added, and washing is carried out with water. The organic phase is dried over sodium sulfate, the solvent is evaporated and the residue is purified by flash chromatography, elution being carried out with a 3/7 methanol/ethyl acetate mixture. 0.052 g of the title compound is obtained. M.p.: 82-84°.

2090E0 ES402001



CLAIMS

1. A compound of formula (I):



where X is N or CH;

A represents a group of formula (a) or (b)



R_1 represents a hydrogen atom or an $-NH_2$, $-NR_3R_4$,
 $-NR_3CO(C_1-C_4)Alk$ or $-NR_3SO_2(C_1-C_4)Alk$ group;

R_2 represents a hydrogen or halogen atom or a
 $(C_1-C_4)Alk$, $(C_1-C_4)alkoxy$, $-COOH$, $-COO$
 $(C_1-C_4)Alk$, $-CN$, $-CONR_3R_4$, $-NO_2$, $-SO_2NR_3R_4$ or
 $-NHSO_2(C_1-C_4)Alk$ group;

m and n each represent 0, 1 or 2;

R_3 and R_4 each represent a hydrogen atom or a $(C_1-C_4)Alk$
group;

Y_1 and Y_2 each represent NH or O;
and their salts or solvates.

2. The compound as claimed in claim 1,

where X represents CH.

3. The compound as claimed in claim 1,
where X represents a nitrogen atom and the R₂ group is
in the 5-position.


4. The compound as claimed in claim 1,
5 where the (C₁-C₄)Alk group is a methyl or ethyl group.

5. The compound as claimed in claim 1,
where R₂ is chosen from -COOH, -COO(C₁-C₄)Alk, -CN, -NO₂,
-CONR₃R₄ and -NHSO₂-(C₁-C₄)Alk.

6. 3-[1-(5-Ethoxycarbonylpyrid-2-yl)-4-
10 piperidinylamino]-1-(1,2-dihydro-2-oxobenzimidazol-4-
yloxy)-2-propanol and its salts or solvates.

7. 3-[1-(5-Ethoxycarbonylpyrid-2-yl)-4-
piperidinylamino]-1-[2-aminopyrid-5-yloxy]-2-propanol
and its salts or solvates.

15 8. A process for the preparation of the
compound of claim 1, characterized in that an epoxide
of formula (II):



20

in which A' represents the group (a) or the group (b)


in which R₁ is optionally protected, where (a), (b) and
R₁ are as defined in claim 1, is reacted with an amine
of formula (III)




(III)

where m, n, R₂ and X are as indicated above, the protective group optionally present is removed and, optionally, the product of formula (I) thus obtained is converted into one of its salts or solvates.

9. A process for the preparation of the compound of claim 1 where A represents a group (b) and R₁ is an NH₂ group, characterized in that a product of formula (II) as defined in claim 8 where A' is the group (b) and R₁ is a group of formula:



15 is reacted with an amine of formula III and the product of formula IV thus obtained:




(IV)


20 is subjected to a hydrogenation reaction in order to

convert the 4-nitrophenyldiazenyl group to an amino group and, optionally, the product of formula (I) thus obtained is converted into one of its salts or solvates.


- 5 10. A process for the preparation of the compound of claim 1 where A represents the group (a) and Y_1 and Y_2 represent a nitrogen atom, characterized in that a compound of formula (V):



is reacted with a compound of formula (III) as defined in claim 8, the nitro group of the product of formula (VI) thus obtained:



is reduced, the product of formula (VII) thus obtained:



is treated with a carbonylation agent, the product of
 formula (I) thus obtained is isolated and, optionally,
 5 is converted into one of its salts or solvates.

11. The process as claimed in claim 10,
 characterized in that the carbonylation agent is chosen
 from carbonyldiimidazole and phosgene.

12. A pharmaceutical composition comprising
 10 at least one compound of claim 1 as active principle.

13. Use of the compound as claimed in claim
 1 for the preparation of medicaments indicated in
 irritable bowel syndrome, or with a modulating effect
 on intestinal motility, lipolytic agent, antiobesity
 15 agent, antidiabetic, psychotropic, antiglaucoma agent,
 cicatrizant or antidepressant, or as tocolytics for
 preventing or delaying premature labor or for the
 treatment and/or prophylaxis of dysmenorrhea.


PATENT

Heteroaryloxypropanolamines, process for their
 preparation and pharmaceutical compositions comprising
 them

On behalf of:
 SANOFI-SYNTHELABO



ABSTRACT

Compounds of formula (I):



where X is N or CH;

A represents a group of formula (a) or (b)



R₁ represents hydrogen or an -NH₂, -NR₃R₄,
 -NR₃CO(C₁-C₄)Alk or -NR₃SO₂(C₁-C₄)Alk group;

R₂ represents hydrogen, a halogen or a
 (C₁-C₄)Alk, (C₁-C₄)alkoxy, -COOH,
 -COO(C₁-C₄)Alk, -CN, -CONR₃R₄, -NO₂, -SO₂NR₃R₄
 or -NHSO₂(C₁-C₄)Alk;

m and n each represent 0, 1 or 2;

10070453-030602

R_3 and R_4 each represent hydrogen or a $(C_1-C_4)Alk$ group;

Y_1 and Y_2 each represent NH or O ;

and their salts or solvates, a process for their preparation and the pharmaceutical compositions comprising them.

10070453-030602

Page 1 of 2

I/We hereby claim benefit under Section 119(e) of Title 35 of the United States Code of any United States provisional application(s) identified below:

Application No.

Filing Date

I/We hereby claim benefit under Section 120 of Title 35 of the United States Code of any United States application(s) or PCT international application(s) designating the United States identified below:

Application Serial No.

Filing Date

Status

2- I/We hereby appoint Michael D. Alexander, Reg. No. 36,080; and Paul E. Dupont, Reg. No. 27,438, or any of them my/our attorneys or agents with full power of substitution and revocation to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO:

DIRECT TELEPHONE CALLS TO:

Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355

Telephone No. _____

I/We hereby declare that all statements made herein and in the above-identified application of my/our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00 Full name of first inventor CECCHI Roberto

Inventor's signature Roberto CECCHI

Date

22/02/02

Mailing Address/Residence

Piazza P. Gobetti, 1 D, I-26900 LODI, ITALIE ITX

Citizenship

Italian ✓

2-00 Full name of second inventor OLIVA Ambrogio

Inventor's signature Ambrogio OLIVA

Date

22/02/02

Mailing Address/Residence

Via Visconti 27, I-21047 SARRONO, ITALIE ITX

Citizenship

Italian ✓